AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 32 min read$TEM

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 1:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 1:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23% — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$TEMBullishMed
01

Why it matters

The guidance suggests a higher growth trajectory than consensus, which could drive the stock higher in the short term.

02

Market read

Strong guidance may attract growth‑oriented investors and boost the broader AI‑health sector.

03

What to watch

Potential reimbursement delays and competitive pressure from Guardant could temper upside.

Relevance 7/10Novelty 7/10Timing: post‑earnings call today

Background

Tempus AI held its Q3 2026 earnings call, providing updated revenue growth guidance and discussing integration of the Personalis acquisition.

Company-level read

Ticker impact

$TEMBullishHigh confidence
Context

Tempus AI disclosed 2026 revenue growth guidance of 25%+ and highlighted 23% Q3 revenue jump, indicating stronger-than-expected performance.

Expected impact

likely upward pressure as investors price in higher growth trajectory

Evidence & confidence

Management emphasized durable 25% growth and near‑term 30% targets, which are above consensus forecasts.

Market effects

Sector

Positive outlook may lift other AI‑enabled health‑tech stocks.

Regional

U.S. biotech/health‑tech sector could see modest gains.

Global

Limited to investors focused on precision‑medicine and AI data platforms.

Counterpoint

What could challenge this read

Growth targets may be overly optimistic given integration risks of Personalis.

Key entities

  • Company
    Tempus AI Inc

    Provider of AI‑driven precision medicine platforms.

  • Company
    Personalis

    Acquired firm whose MRD test is being integrated.

Read at source← All news

StoryTempus AI posts record Q3 revenue, first adjusted profit and raises full‑year outlook

Also covered by

6 outlets

Related articles

NOV 2
$TEMMedAI 8/10

Tempus AI (TEM): Oncology Volume Surge and Data Licensing Bookings Signal a Profitable Inflection

Tempus AI (TEM) reported Q3 2026 revenue of $411.5M, up 23% YoY, with adjusted EBITDA of $25.6M. Oncology revenue grew 28% to $172.6M, while Data and Applications revenue increased 33% to $108.1M. The company raised full-year revenue guidance to $1.60B-$1.605B and expects near-term catalysts from reimbursement improvements and the pending $1.7B Personalis acquisition.

news.alphastreet.com7 min